Silo Pharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Intranasal delivery of spc-15 shows rapid and effective drug exposure for ptsd therapy sarasota, fl, april 23, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced positive data in the final validation report from the recent pharmacokinetic (pk) study of spc-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (ptsd). the pk study was conducted as part of non-glp small animal dose-ranging study of spc-15 completed in february 2024.

Spc-14 shows cognitive and stress reduction benefits in preclinical models sarasota, fl, april 10, 2024 (globe newswire) --  silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has exercised its option to license alzheimer's disease (ad) therapeutic spc-14 from columbia university, pursuant to a sponsored research and option agreement established in 2021. under the terms of the license agreement currently in process, silo will be granted an exclusive license to further develop, manufacture, and commercialize spc-14 worldwide upon consummation of such agreement.

Silo reports positive stability of sp-26 for time-release and dosage control sarasota, fl, march 18, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has filed a provisional patent application titled ‘methods and combinations for managing pain' with the united states patent and trademark office (uspto). the patent application includes protection for the company's sp-26 implantable drug delivery system for a novel time-released, dose-controlled formulation of ketamine, initially targeted for fibromyalgia.

All animal subjects tolerated maximum dosing once-per-day human intranasal dosing regimen determined for clinical evaluation sarasota, fl, feb. 28, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced positive results from its non-glp small animal dose-ranging study of spc-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (ptsd). the purpose of the non-glp small animal study was to identify the maximum tolerated intranasal dose of the drug pharmacokinetic and determine the therapeutically relevant dose range to be studied in clinical trials.

Initial indications target fibromyalgia and chronic pain loaded and encapsulated drug maintains structural stability as implantable treatment sarasota, fl, feb. 14, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today provided a positive update on sp-26, its novel time-released, dose-controlled formulation of ketamine initially targeted for fibromyalgia. a pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability.

Silo Pharma shares rose on Tuesday after the development stage biopharmaceutical company announced it has advanced the formulation development of its therapeutic candidate SPC-15, achieving a liquid nasal formulation. This formulation of SPC-15, a targeted prophylactic treatment using ketamine compositions, is being investigated as a method of treatment and prevention of anxiety, post-traumatic stress disorder (PTSD) and other stress disorders.

ENGLEWOOD CLIFFS, NJ, April 24, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.  (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that James Kuo, M.D., Vice President of R&D, will speak at the 3rd Annual Psychedelic Therapeutics and Drug Development Conference being held May 15-16, 2023, in person, at the Hilton San Francisco Airport Bayfront in Burlingame, CA.

Penny Stocks With News Light Up The Scanners This Week This week

Are you using these penny stocks trading strategies? The post 3 Essential Strategies for Penny Stocks Trading in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny stocks to watch this week with news before 2023. The post Best Penny Stocks To Buy Before 2023?

Although the concept of millionaire-maker stocks will always attract attention, at the moment, investors must realize the rules have changed. Fundamentally, the Federal Reserve remains committed to attacking the inflation crisis through hiking the benchmark interest rate.

Silo Pharma (NASDAQ: SILO ) stock is falling on Thursday despite the company releasing positive data from a pre-clinical study. This data covers the use of SPC-14 as a therapeutic treatment for Alzheimer's disease.

Source: Bukhta Yurii / Shutterstock.com Silo Pharma (NASDAQ: SILO ) stock is in the news Wednesday as investors react to the company uplisting shares. This saw shares of SILO stock switch from the OTC Market to the Nasdaq Exchange yesterday.

In today's turbulent market, what was once green is now red for many companies across all major indices. That said, among today's bigger losers is Silo Pharma (NASDAQ: SILO ), as this early-stage biotech stock is set for its Nasdaq initial public offering (IPO).

Englewood Cliffs NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received approval from the DEA to advance the development of their Z-pod technology in combination with Ketamine.